Meeting
2018 ASCO Annual Meeting
Image-based risk score to predict recurrence of ER+ breast cancer in ECOG-ACRIN Cancer Research Group E2197.
Authors
Nishant Verma
Inspirata, Tampa, FL, US
Nishant Verma , Dave Harding , Amir Mohammadi , Lori J. Goldstein , Hannah L. Gilmore , Michael D Feldman , John Tomaszewski , Ajay Basavanhally , Mark Lloyd , Pingfu Fu , Shridar Ganesan , Nancy E. Davidson , Anant Madabhushi , James Monaco
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 36, 2018 (suppl; abstr 540)
DOI
10.1200/JCO.2018.36.15_suppl.540
Abstract #
540
Poster Bd #
32
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neo-adjuvant chemotherapy in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer.
First Author: Hatem Hussein Soliman
Poster
2023 ASCO Annual Meeting
lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC).
First Author: Charles Geyer
Poster
2023 ASCO Annual Meeting
Correlation between Oncotype DX, Predict, and Nottingham Prognostic Index on HR+, HER2- early breast cancer treatment: The current value of molecular testing.
First Author: Leticia Campoverde
Poster
2022 ASCO Annual Meeting
Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer.
First Author: Christopher David Walden